Skip to content

Application of penehyclidine hydrochloride in painless ultrasound gastroscopy

Application of penehyclidine hydrochloride in painless ultrasound gastroscopy

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100047329
Enrollment
Unknown
Registered
2021-06-12
Start date
2021-07-01
Completion date
Unknown
Last updated
2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless ultrasound gastroscopy

Interventions

Penehyclidine hydrochloride group:Intravenous injection 0.01mg/kg 30min before anesthesia
Blank control group:Normal saline 2ml

Sponsors

Shanghai Changhai Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 18 to 70 years, male or female; 2. ASA I~III; 3. Patients who intend to undergo painless ultrasound gastroscopy; 4. BMI 18.5-28kg/m2; 5. The patient volunteered to participate and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with contraindication of routine endoscopic procedures or refusal of sedation/anesthesia; 2. Unproperly controlled and potentially life-threatening circulatory and respiratory diseases, such as uncontrolled severe hypertension, severe arrhythmia, unstable angina pectoris, acute respiratory infections, asthma attacks, etc.; 3. Liver dysfunction (Child-Pugh grade C or above), acute upper gastrointestinal bleeding with shock, severe anemia, gastrointestinal obstruction with retention of gastric contents; 4. No escort or guardian; 5. Patients with a history of facial and neck trauma, potential ventilation difficulties, snoring, or sleep apnea syndrome; 6. Patients with glaucoma; 7. Long-term opioid treatment; 8. Drug abuse or drug abuse patients; 9. Elderly patients with severe prostatic hypertrophy; 10. Allergic history of narcotic drugs.

Design outcomes

Primary

MeasureTime frame
Incidence of cough and body movement;

Secondary

MeasureTime frame
Sedation level;Number of times of hypoxemia;Testing Time;Physician Satisfaction;

Countries

China

Contacts

Public ContactWang Jiafeng

Shanghai Changhai Hospital

feng_smmu@hotmail.com+86 13774286926

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026